ONCO stock plunges to 52-week low, touches $0.32

In a challenging year for Blue Water Vaccines, the company’s stock (ONCO) has hit a 52-week low, dropping to a price level of $0.32. With a market capitalization of just $2.65 million and a notably low Price/Book ratio of 0.08, InvestingPro analysis suggests the stock is currently undervalued, though significant risks remain. This significant downturn reflects a staggering 1-year change, with the stock value plummeting by -95.27%. Investors have watched with concern as the stock struggled throughout the year, culminating in this latest low point. InvestingPro data reveals concerning fundamentals, including a negative EBITDA of -$13.1M and a high beta of 3.17, indicating significant volatility. The company’s current ratio of 0.06 suggests potential liquidity challenges. For deeper insights, investors can access 18 additional ProTips and a comprehensive Pro Research Report covering ONCO’s financial health and future prospects.

In other recent news, Oncopeptides reported a strong performance in Q4 2024, with a notable 35% increase in European sales compared to the previous quarter. The company’s full-year sales reached SEK 31.6 million, a significant rise from SEK 10.9 million in 2023, driven by strategic market expansions in key European countries like Spain and Germany. Oncopeptides’ Q4 revenue was SEK 9.9 million, and the company ended the year with a cash position of SEK 179 million. The company is also making strides in regulatory progress in Japan and South Korea, potentially opening new revenue streams. Oncopeptides aims for cash flow positivity by the end of 2026, with the first sales in Italy anticipated in the first half of 2025. Additionally, Oncopeptides is in advanced negotiations for a licensing deal in Japan, which could have a significant financial impact. The company’s marketing and sales costs increased to SEK 43 million in Q4, reflecting ongoing commercialization activities. Analyst firms such as Redi and DNB Markets have shown interest in the company’s developments, although no specific upgrades or downgrades were mentioned.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.